कृपया अन्य खोज का प्रयास करें
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Lee Sweeney | - | - | Member of Scientific Advisory Board |
Jonathan C. Fox | 67 | 2023 | Independent Director |
Peter A. Thompson | 64 | 2017 | Co-Founder & Independent Chairman |
Kevin Koch | 64 | 2017 | President, CEO & Director |
Jonathan D. Root | 64 | 2019 | Independent Director |
Badreddin Edris | 37 | 2017 | Co-Founder & Independent Director |
Barry J. Byrne | - | - | Member of Scientific Advisory Board |
Leslie A. Leinwand | - | - | Member of Scientific Advisory Board |
Laura A. Brege | 66 | 2020 | Independent Director |
Craig McDonald | - | 2020 | Member of the Scientific Advisory Board |
Alan J. Russell | 54 | 2017 | Co-Founder, Chief Scientific Officer & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है